Cargando…
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer
Oncolytic strains of vaccinia virus are currently in clinical development with clear evidence of safety and promising signs of efficacy. Addition of therapeutic genes to the viral genome may increase the therapeutic efficacy of vaccinia. We evaluated the therapeutic potential of vaccinia virus expre...
Autores principales: | Mansfield, D C, Kyula, J N, Rosenfelder, N, Chao-Chu, J, Kramer-Marek, G, Khan, A A, Roulstone, V, McLaughlin, M, Melcher, A A, Vile, R G, Pandha, H S, Khoo, V, Harrington, K J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827015/ https://www.ncbi.nlm.nih.gov/pubmed/26814609 http://dx.doi.org/10.1038/gt.2016.5 |
Ejemplares similares
-
Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter
por: Haddad, Dana, et al.
Publicado: (2012) -
Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis
por: Wilkinson, Michelle J., et al.
Publicado: (2016) -
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism
por: McLaughlin, Martin, et al.
Publicado: (2020) -
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies
por: Roulstone, Victoria, et al.
Publicado: (2021) -
Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010)